# A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

> **NCT02742051** · PHASE2 · COMPLETED · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 40 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Letrozole
- **DRUG:** Fluorouracil
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02742051
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2020-03-14
- **Final completion:** 2020-03-14
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02742051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02742051, "A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02742051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*